TrialSignal
Clinical trial intelligence report
A Phase 1 Study Consisting of a Double-Blind, Placebo Controlled Multiple Dose Study of TRx0037 in Healthy Elderly Volunteers
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT01253499-Jul 28, 2026
NCT ID
NCT01253499
Status
COMPLETED
Phase
PHASE1
Sponsor
TauRx Therapeutics Ltd
Executive brief
Investment-Ready Snapshot
A Phase 1 Study Consisting of a Double-Blind, Placebo Controlled Multiple Dose Study of TRx0037 in Healthy Elderly Volunteers is a PHASE1 clinical asset sponsored by TauRx Therapeutics Ltd in Alzheimer's Disease. SEO and diligence focus: TRx0037, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01253499
Indication
Alzheimer's Disease
Modality
small molecule
Target
TRx0037
Intervention
TRx0037
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.